# EDGAR Filing Document

**Accession Number:** 0001858745
**File Stem:** 0001193125-26-138044
**Filing Date:** 2026-4
**Character Count:** 9817
**Document Hash:** 3b8bf32adee258cf2c7001665c9f2f4f
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-26-138044.hdr.sgml**: 20260401

**ACCESSION NUMBER**: 0001193125-26-138044

**CONFORMED SUBMISSION TYPE**: 3

**PUBLIC DOCUMENT COUNT**: 2

**CONFORMED PERIOD OF REPORT**: 20260318

**FILED AS OF DATE**: 20260401

**DATE AS OF CHANGE**: 20260401

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Levy Elliott M.
- **CENTRAL INDEX KEY:** 0001858745

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** 3
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-38215
- **FILM NUMBER:** 26828793

**MAIL ADDRESS:**
- **STREET 1:** C/O OMEGA THERAPEUTICS, INC.
- **STREET 2:** 20 ACORN PARK D
- **CITY:** CAMBRIDGE
- **STATE:** MA
- **ZIP:** 02140
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** NuCana plc
- **CENTRAL INDEX KEY:** 0001709626
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** X0
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** 3 LOCHSIDE WAY
- **CITY:** EDINBURGH
- **STATE:** X0
- **ZIP:** EH12 9DT
- **BUSINESS PHONE:** 44-0-131-357-1111

**MAIL ADDRESS:**
- **STREET 1:** 3 LOCHSIDE WAY
- **CITY:** EDINBURGH
- **STATE:** X0
- **ZIP:** EH12 9DT

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** NuCana BioMed Ltd
- **DATE OF NAME CHANGE:** 20170619

## Exhibit 24.1

**POWER OF ATTORNEY**

Know all by these presents, that the undersigned hereby constitutes and appoints each of Hugh Griffith and Ian Webster, the Chief Executive Officer and Interim Chief Financial Officer, respectively, of NuCana plc (the "Company"), and John T. Rudy, Allyson Wilkinson, Gianna M. Nappi, Michelle St Francis, Robyn M. Frattali and Autumn N. Mays of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., signing singly, with full power of substitution, the undersigned's true and lawful attorney-in-fact to:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1)execute for and on behalf of the undersigned, in the undersigned's capacity as a director of the Company, forms and authentication documents for EDGAR Filing Access;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2)do and perform any and all acts for and on behalf of the undersigned that may be necessary or desirable to complete and execute any such forms and authentication documents;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(3)execute for and on behalf of the undersigned, in the undersigned's capacity as a director of the Company, Forms 3, 4 and 5 in accordance with Section 16(a) of the Securities Exchange Act of 1934, as amended, and the rules thereunder;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(4)do and perform any and all acts for and on behalf of the undersigned that may be necessary or desirable to complete and execute any such Form 3, 4 or 5 and timely file such form with the United States Securities and Exchange Commission and any stock exchange or similar authority; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(5)take any other action of any type whatsoever in connection with the foregoing that, in the opinion of such attorney-in-fact, may be of benefit to, in the best interests of, or legally required by the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact's discretion.

The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is the Company assuming, any of the undersigned's responsibilities to comply with Section 16 of the Securities Exchange Act of 1934, as amended.

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4 and 5 with respect to the undersigned's holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorneys-in-fact.

------

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of the date set forth below.

---

| | | |
|:---|:---|:---|
| Date: 4/1/2026 | By: | /s/ Elliott Levy |
|  |  | Name: Elliott Levy |

---

------

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 3

### INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Levy Elliott M.<br><sub>(Last) (First) (Middle)</sub><br>C/O NUCANA PLC<br>3 LOCHSIDE WAY<br><sub>(Street)</sub><br>EDINBURGH, UNITED KINGDOM EH12 9DT<br><sub>(City) (State) (Zip)</sub> | **3. Issuer Name and Ticker or Trading Symbol**<br>NuCana plc [ NCNA ] | **5. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  |
| **2. Date of Event Requiring Statement (Month/Day/Year)**<br>2026-03-18 | **4. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[X] Director   [ ] 10% Owner<br>[ ] Officer (give title below)   [ ] Other (specify below)<br>_ _ | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities Beneficially Owned

---

|  |  |  |  |
| --- | --- | --- | --- |
| 1. Title of Security | 2. Amount of Securities Beneficially Owned | 3. Ownership Form | 4. Nature of Indirect Beneficial Ownership |
| Ordinary Shares | 13 | D |  |

---

## Table II - Derivative Securities Beneficially Owned

---

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 3. Title and Amount of Underlying Securities | 3. Title and Amount of Underlying Securities | 4. Conversion or Exercise Price | 5. Ownership Form | 6. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 4. Conversion or Exercise Price | 5. Ownership Form | 6. Nature of Indirect Beneficial Ownership |
| American Depositary Shares | <sup>(1)</sup> | <sup>(1)</sup> | Ordinary Shares | 3 | <sup>(1)</sup> | D |  |
| Options | <sup>(2)</sup> | <sup>(2)</sup> | Ordinary Shares | 23811896 | <sup>(2)</sup> | D |  |
| Options | <sup>(3)</sup> | <sup>(3)</sup> | Ordinary Shares | 23811896 | <sup>(3)</sup> | D |  |
| Options | <sup>(4)</sup> | <sup>(4)</sup> | Ordinary Shares | 28631517 | <sup>(4)</sup> | D |  |
| Options | <sup>(5)</sup> | <sup>(5)</sup> | Ordinary Shares | 28631517 | <sup>(5)</sup> | D |  |

---

### Footnotes:

(1) Each American Depositary Share ("ADS") represents 5,000 ordinary shares, nominal value 0.0004 Pounds Sterling per share (the "Ordinary Shares"), of NuCana plc (the "Company"). ADSs have no expiration date.

(2) The Ordinary Shares underlying this option have an exercise price of 0.004 Pounds Sterling, completed vesting on June 20, 2025 and expire June 20, 2035.

(3) The Ordinary Shares underlying this option have an exercise price of 0.0004 Pounds Sterling and will vest in full on June 20, 2026, subject to the Reporting Person's continued service with the Company through the applicable vesting date.

(4) The Ordinary Shares underlying this option have an exercise price of 0.0005 Pounds Sterling, completed vesting on January 14, 2026 and expire January 14, 2036.

(5) The Ordinary Shares underlying this option have an exercise price of 0.0004 Pounds Sterling and will vest in full on January 14, 2027, subject to the Reporting Person's continued service with the Company through the applicable vesting date.

**Remarks:**
This Form 3 is being filed late due to unanticipated delays in receiving the Reporting Person's EDGAR codes, which delays the Reporting Person understands were due to the high volume of applications at the time.

Exhibit 24.1 - Power of Attorney

**Signature:** /s/ Ian Webster, Attorney-in-Fact for Elliott Levy  
**Date:** 2026-04-01

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**